Athyros VG - Search Results

1

Novel Data on the Prevalence, Identification, Scouting, and Treatment of Familial Hypercholesterolaemia.

Doumas M, Imprialos K, Stavropoulos K, Athyros VG. Doumas M, et al. Among authors: athyros vg. Curr Pharm Des. 2018;24(31):3597-3598. doi: 10.2174/138161282431181224144112. Curr Pharm Des. 2018. PMID: 30642238

2

Atenolol: differences in mode of action compared with other antihypertensives. An opportunity to identify features that influence outcome?

Karagiannis A, Mikhailidis DP, Kakafika AI, Tziomalos K, Athyros VG. Karagiannis A, et al. Among authors: athyros vg. Curr Pharm Des. 2007;13(2):229-39. doi: 10.2174/138161207779313713. Curr Pharm Des. 2007. PMID: 17269930 Review.

3

Pleiotropic effects of statins--clinical evidence.

Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP. Athyros VG, et al. Curr Pharm Des. 2009;15(5):479-89. doi: 10.2174/138161209787315729. Curr Pharm Des. 2009. PMID: 19199976 Review.

4

Ezetimibe therapy for dyslipidemia: an update.

Katsiki N, Theocharidou E, Karagiannis A, Athyros VG, Mikhailidis DP. Katsiki N, et al. Among authors: athyros vg. Curr Pharm Des. 2013;19(17):3107-14. doi: 10.2174/13816128113199990314. Curr Pharm Des. 2013. PMID: 23317398 Review.

5

Colesevelam: a new and improved bile acid sequestrant?

Tziomalos K, Karagiannis A, Mikhailidis DP, Athyros VG. Tziomalos K, et al. Among authors: athyros vg. Curr Pharm Des. 2013;19(17):3115-23. doi: 10.2174/1381612811319170019. Curr Pharm Des. 2013. PMID: 23317402 Review.

6

Prehypertension and the cardiometabolic syndrome: targeting several risk factors to achieve maximum benefit.

Katsiki N, Doumas M, Athyros VG, Karagiannis A. Katsiki N, et al. Among authors: athyros vg. Expert Rev Cardiovasc Ther. 2014 Mar;12(3):295-6. doi: 10.1586/14779072.2014.890051. Epub 2014 Feb 10. Expert Rev Cardiovasc Ther. 2014. PMID: 24506503

7

Treating Arterial Stiffness in Young and Elderly Patients with the Metabolic Syndrome.

Tziomalos K, Athyros VG, Karagiannis A. Tziomalos K, et al. Among authors: athyros vg. Curr Pharm Des. 2014;20(39):6106-13. doi: 10.2174/1381612820666140417101523. Curr Pharm Des. 2014. PMID: 24745924 Review.

8

The 2013 American College of Cardiology/American Heart Association guidelines for the treatment of dyslipidemia: mind the gaps!

Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Athyros VG, et al. Curr Med Res Opin. 2014 Sep;30(9):1701-5. doi: 10.1185/03007995.2014.924488. Epub 2014 Jun 4. Curr Med Res Opin. 2014. PMID: 24827374

9

Novel data on the pathogenesis of atherosclerosis, treatment targets, and new therapeutic interventions in lipid-related cardiovascular risk factors.

Athyros VG, Tziomalos K, Katsiki N, Mikhailidis DP. Athyros VG, et al. Curr Pharm Des. 2014;20(40):6215-9. doi: 10.2174/1381612820666140622201940. Curr Pharm Des. 2014. PMID: 24953387 No abstract available.

10

Effects of lipid-lowering agents on inflammation, haemostasis and blood pressure.

Tziomalos K, Karagiannis A, Athyros VG. Tziomalos K, et al. Among authors: athyros vg. Curr Pharm Des. 2014;20(40):6306-13. doi: 10.2174/1381612820666140622201452. Curr Pharm Des. 2014. PMID: 24953388 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

393 results

Search Page

Filters